PE20240656A1 - Anticuerpos anti-cd20 y estructuras car-t - Google Patents
Anticuerpos anti-cd20 y estructuras car-tInfo
- Publication number
- PE20240656A1 PE20240656A1 PE2023002858A PE2023002858A PE20240656A1 PE 20240656 A1 PE20240656 A1 PE 20240656A1 PE 2023002858 A PE2023002858 A PE 2023002858A PE 2023002858 A PE2023002858 A PE 2023002858A PE 20240656 A1 PE20240656 A1 PE 20240656A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- car
- structures
- seq
- amino acid
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se refiere a anticuerpos anti-CD20 caracterizado porque comprende una region variable de cadena pesada que comprende: (a) una secuencia de CDR1 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 1 o 4; y/o (b) una secuencia de CDR2 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 2 o 5; y/o (c) una secuencia de CDR3 que comprende dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NO: 3 o 6. Tambien se refiere a que dichos anticuerpos estan en formato CAR-T, multiespecificos. Ademas, se refiere a metodos para producir dichos anticuerpos y estructuras CAR-T, composiciones, composiciones farmaceuticas que comprenden dichos anticuerpos y estructuras CAR-T, y su uso para tratar trastornos que se caracterizan por la expresion de CD20, tales como linfoma no de Hodgkin (NHL), leucemia linfocitica cronica (CLL), entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176161P | 2021-04-16 | 2021-04-16 | |
| PCT/US2022/025077 WO2022221698A1 (en) | 2021-04-16 | 2022-04-15 | Anti-cd20 antibodies and car-t structures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240656A1 true PE20240656A1 (es) | 2024-04-04 |
Family
ID=81585457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002858A PE20240656A1 (es) | 2021-04-16 | 2022-04-15 | Anticuerpos anti-cd20 y estructuras car-t |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240117063A1 (es) |
| EP (1) | EP4323403A1 (es) |
| JP (1) | JP2024513951A (es) |
| KR (1) | KR20230171952A (es) |
| CN (1) | CN117337303A (es) |
| AU (1) | AU2022259688A1 (es) |
| BR (1) | BR112023021225A2 (es) |
| CA (1) | CA3215241A1 (es) |
| CL (1) | CL2023003073A1 (es) |
| CO (1) | CO2023013543A2 (es) |
| CR (1) | CR20230525A (es) |
| IL (1) | IL306045A (es) |
| MX (1) | MX2023012181A (es) |
| PE (1) | PE20240656A1 (es) |
| WO (1) | WO2022221698A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| NZ538996A (en) | 2002-10-31 | 2008-04-30 | Genentech Inc | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP3272770B1 (en) | 2004-07-22 | 2023-12-20 | Erasmus University Medical Center Rotterdam | Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| PT2406284T (pt) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anticorpos anti-bcma |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US11613572B2 (en) | 2016-06-21 | 2023-03-28 | Teneobio, Inc. | CD3 binding antibodies |
| WO2018039180A1 (en) | 2016-08-24 | 2018-03-01 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| US10246514B2 (en) * | 2016-09-12 | 2019-04-02 | The United States Of America, As Represented By The Secretary Of The Navy | Single domain antibodies that bind to human CD20 |
| BR122022002481A8 (pt) | 2016-09-14 | 2023-02-07 | Teneobio Inc | Anticorpos biespecíficos de ligação específica para cd3delta-epsilon |
| US20220218745A1 (en) * | 2017-12-22 | 2022-07-14 | 2Seventy Bio, Inc. | Multivalent chimeric antigen receptor |
| US20220195068A1 (en) * | 2019-04-05 | 2022-06-23 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
-
2022
- 2022-04-15 JP JP2023562540A patent/JP2024513951A/ja active Pending
- 2022-04-15 BR BR112023021225A patent/BR112023021225A2/pt unknown
- 2022-04-15 IL IL306045A patent/IL306045A/en unknown
- 2022-04-15 MX MX2023012181A patent/MX2023012181A/es unknown
- 2022-04-15 CA CA3215241A patent/CA3215241A1/en active Pending
- 2022-04-15 PE PE2023002858A patent/PE20240656A1/es unknown
- 2022-04-15 AU AU2022259688A patent/AU2022259688A1/en active Pending
- 2022-04-15 EP EP22721975.5A patent/EP4323403A1/en active Pending
- 2022-04-15 CR CR20230525A patent/CR20230525A/es unknown
- 2022-04-15 KR KR1020237038039A patent/KR20230171952A/ko unknown
- 2022-04-15 WO PCT/US2022/025077 patent/WO2022221698A1/en active Application Filing
- 2022-04-15 CN CN202280027742.6A patent/CN117337303A/zh active Pending
-
2023
- 2023-09-25 US US18/473,965 patent/US20240117063A1/en active Pending
- 2023-10-13 CO CONC2023/0013543A patent/CO2023013543A2/es unknown
- 2023-10-16 CL CL2023003073A patent/CL2023003073A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230525A (es) | 2024-02-19 |
| BR112023021225A2 (pt) | 2023-12-19 |
| AU2022259688A1 (en) | 2023-10-05 |
| CO2023013543A2 (es) | 2023-10-30 |
| MX2023012181A (es) | 2023-12-15 |
| WO2022221698A1 (en) | 2022-10-20 |
| CN117337303A (zh) | 2024-01-02 |
| CL2023003073A1 (es) | 2024-04-19 |
| CA3215241A1 (en) | 2022-10-20 |
| IL306045A (en) | 2023-11-01 |
| JP2024513951A (ja) | 2024-03-27 |
| EP4323403A1 (en) | 2024-02-21 |
| US20240117063A1 (en) | 2024-04-11 |
| KR20230171952A (ko) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240656A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| PE20190356A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
| PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| RU2018112649A (ru) | Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство | |
| PE20181323A1 (es) | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina | |
| EA202192736A1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с псма | |
| MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| PE20140196A1 (es) | Anticuerpos anti-cd37 | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| PE20141019A1 (es) | Nuevos inmunoconjugados | |
| PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
| BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| MX2013009151A (es) | Inmunoterapia mejorada. | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
| MX2023005081A (es) | Anticuerpos multiespecificos para dirigirse a cd28 y pd-l1 y metodos de uso de los mismos. |